Why the study?
Despite improvements with second-generation drug-eluting stents after PCI, patients with diabetes mellitus continue to experience high rates of ischemic and bleeding complications.
Do bleeding and ischemic risk factors increase the risk of MACE and major bleeding in diabetic patients undergoing PCI with everolimus-eluting stents?
Do bleeding and ischemic risk factors increase the risk of MACE and major bleeding in diabetic patients undergoing PCI with everolimus-eluting stents?
In diabetic patients undergoing PCI, bleeding risk factors, but not commonly used ischemic risk factors, are associated with a higher risk of both long-term ischemic and bleeding events.
Answers are grounded in this paper and cite their sources.
Bleeding risk factors warrant caution in DM patients post-PCI; leaves open whether integrated stratification improves outcomes.
OBJECTIVE: To investigate the impact of ischemic and bleeding risk factors on long-term clinical outcomes of patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) with everolimus-eluting stents. BACKGROUND: Second-generation drug-eluting stents have substantially improved outcomes after PCI in the general population; however, DM patients continue to experience high rates of ischemic and bleeding complications. METHODS: DM patients from the pooled XIENCE V registry were divided into high or low bleeding and ischemic risk groups (HBR, LBR, HIR, and LIR) based on established bleeding (age ≥ 75 years; chronic kidney disease; anemia; prior stroke; oral anticoagulation; thrombocytopenia; prior major bleeding) and ischemic (acute coronary syndrome; prior myocardial infarction [MI]; ≥3 stents implanted; ≥3 vessels treated; ≥3 lesions treated; stent length > 60 mm; bifurcation treated with ≥2 stents; chronic total occlusion) risk factors. The primary outcomes were major adverse cardiac events (MACE; cardiac death, MI, or stent thrombosis) and major bleeding at 4-year follow-up. RESULTS: A total of 3,704 DM patients were divided into four groups (21.5% LBR/LIR; 39.0% LBR/HIR; 15.6% HBR/LIR; 23.9% HBR/HIR). Compared with LBR/LIR patients, those at HBR/HIR and HBR/LIR had a significantly higher risk of MACE (HR (95% CI) 2.7 (1.9-3.9) and 2.2 (1.5-3.2), respectively) and major bleeding (2.7 (1.6-4.8) and 2.6 (1.4-4.7), respectively), while LBR/HIR patients did not. CONCLUSIONS: Among DM patients undergoing PCI, presence of bleeding risk factors was associated with a higher risk of both ischemic and bleeding events, whereas commonly used features of ischemic risk did not impact long-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Goel et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: